1 November 2020 in Journal of the American Academy of Dermatology
BNBeau R. van Nieuwenhuizen
Beau R. van Nieuwenhuizen
+2
Evidence on long-term dupilumab treatment for atopic dermatitis in daily practice is lacking. To investigate patient characteristics, treatment aspects, effectiveness and safety of up to 84 weeks of dupilumab treatment. An observational prospective cohort study was conducted, including atopic dermatitis patients starting dupilumab in routine clinical care. Of the 221 included patients, 103 used systemic therapy at baseline. At 84 weeks we found a change of -15.2 (SE 1.7) for EASI, -16.9 (SE 1.4) for POEM, -17.2 (SE 1.6) for DLQI. As for IGA and NRS pruritus, we found a trend for improvement over time. Severe (n=79) including serious (n=11) adverse events were observed in 69 patients. Eye complaints were most frequently reported (n=46). Twenty-one patients adjusted the regular dosing schedule. Fourteen patients discontinued treatment, mainly due to ineffectiveness (n=7). Only adverse events of severe and serious nature were registered for feasibility reasons. Daily practice dupilumab treatment up to 84 weeks is generally well-tolerated, apart from the reporting of eye complaints. It can be considered a long-term effective treatment for atopic dermatitis in combination with topical and initial concomitant systemic treatment, showing a sustained improvement of signs, symptoms and quality of life.
25 February 2022 in Journal of the European Academy of Dermatology and Venereology
Atopic dermatitis is a heterogeneous disease, accompanied by a wide variation in disease presentation and the potential to identify many phenotypes that may be relevant for prognosis and treatment. We aimed to systematically review previously reported phenotypes of atopic dermatitis and any characteristics associated with them. Ovid EMBASE, Ovid MEDLINE and Web of Science were searched from inception till 12 February 2021 for studies attempting to classify atopic dermatitis. Primary outcomes are atopic dermatitis phenotypes and characteristics associated with them in subsequent analyses. A secondary outcome is the methodological approach used to derive them. In total, 8511 records were found. By focussing only on certain clinical phenotypes, 186 studies were eligible for inclusion. The majority of studies were hospital‐based (59%, 109/186) and cross‐sectional (76%, 141/186). The number of included patients ranged from seven to 526 808. Data‐driven approaches to identify phenotypes were only used in a minority of studies (7%, 13/186). Ninety‐one studies (49%) investigated a phenotype based on disease severity. A phenotype based on disease trajectory, morphology and eczema herpeticum was investigated in 56 (30%), 22 (12%) and 11 (6%) studies respectively. Thirty‐six studies (19%) investigated morphological characteristics in other phenotypes. Investigated associated characteristics differed between studies. In conclusion, we present an overview of phenotype definitions used in literature for severity, trajectory, morphology and eczema herpeticum, including associated characteristics. There is a lack of uniform and consistent use of atopic dermatitis phenotypes across studies.
4 February 2019 in British Journal of Dermatology
TTthe International TREAT Registry Taskforce
the International TREAT Registry Taskforce
+12
Background Comparative, real‐life and long‐term evidence on the effectiveness and safety of photo‐ and systemic therapy in moderate‐to‐severe atopic eczema (AE) is limited. Such data must come from well‐designed prospective patient registries. Standardisation of data collection is needed for direct comparisons and data pooling. Objectives To reach consensus on how and when to measure the previously defined domain items of the TREatment of Atopic eczema (TREAT) Registry Taskforce core dataset for research registries for paediatric and adult AE patients. Methods Proposals for the measurement instruments were based on the recommendations of the Harmonising Outcome Measures for Eczema (HOME) initiative, the existing AE database of TREATgermany, expert opinions and systematic reviews of the literature. The proposals were discussed at multiple face‐to‐face consensus meetings, one teleconference and via email. The frequency of follow‐up visits was determined by an expert survey. Results A total of 16 experts from 7 countries participated in the ‘how to measure’ consensus process and 12 external experts were consulted. Consensus was reached for all domain items on how they should be measured by assigning measurement instruments. A minimum follow‐up frequency of initially 4 weeks after commencing treatment, then every 3 months while on treatment and every 6 months while off treatment was defined. Conclusions This core dataset for national AE research registries will aid the comparability and pooling of data across centres and country borders and enable international collaboration to assess the long‐term effectiveness and safety of photo‐ and systemic therapy used in patients with AE.
10 May 2021 in Clinical and Experimental Dermatology
Dupilumab is a relatively new treatment option for patients with moderate‐to‐severe atopic dermatitis. There is a lack of knowledge about treatment with dupilumab during conception in both males and females, as well as during pregnancy and lactation. We report four patients who expressed a wish to conceive during treatment with dupilumab in daily practice. Two male patients conceived during dupilumab treatment, and two female patients discontinued dupilumab because of anticipated pregnancy. Apart from disease flares in both patients that discontinued treatment, no complications were reported concerning the ability to conceive, the pregnancy and fetal outcomes. We present an overview of the current available literature on dupilumab during conception, pregnancy and lactation that can guide considerations for patients on dupilumab wishing to conceive a child. Preference is given to treatment with topical corticosteroids, phototherapy, systemic corticosteroids and ciclosporin, until more data is available.
24 August 2019 in British Journal of Dermatology
10 September 2022 in Journal of the European Academy of Dermatology and Venereology
MMMaritza A. Middelkamp‐Hup
Maritza A. Middelkamp‐Hup
+20
Background: The TREatment of ATopic eczema (TREAT) Registry Taskforce is a collaborative international network of registries collecting data of atopic eczema (AE) patients receiving systemic and phototherapy with the common goal to provide long‐term real‐world data on the effectiveness, safety and cost‐effectiveness of therapies. A core dataset, consisting of domains and domain items with corresponding measurement instruments, has been developed to harmonize data collection.Objectives: We aimed to give an overview of the status and characteristics of the eight established TREAT registries, and to perform a mapping exercise to examine the degree of overlap and pooling ability between the national registry datasets. This will allow us to determine which research questions can be answered in the future by pooling data.Methods: All eight registries were asked to share their dataset and information on the current status and characteristics. The overlap between the core dataset and each registry dataset was identified (according to the domains, domain items and measurement instruments of the TREAT core dataset).Results and conclusions: A total of 4702 participants have been recruited in the eight registries as of 1st of May 2022. Of the 69 core dataset domain items, data pooling was possible for 69 domain item outcomes in TREAT NL (the Netherlands), 61 items in A‐STAR (UK and Ireland), 38 items in TREATgermany (Germany), 36 items in FIRST (France), 33 items in AtopyReg (Italy), 29 items in Biobadatop (Spain), 28 items in SCRATCH (Denmark) and 20 items in SwedAD (Sweden). Pooled analyses across all registries can be performed on multiple important domain items, covering the main aims of analysing data on the (cost‐)effectiveness and safety of AE therapies. These results will facilitate future comparative or joint analyses.